NS Healthcare is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
Home » Companies » Thermo Fisher Scientific

Thermo Fisher Scientific - Procalcitonin for neonatal sepsis diagnosis and safe antibiotic guidance

About Thermo Fisher Scientific

Neonatal sepsis is a leading cause of global mortality in children under five years old. According to the Global Sepsis Alliance, infections leading to sepsis are responsible for about one fifth of the world's annual 2.7 million neonatal deaths, especially in South Asia and sub-Saharan Africa.


Products & Services
NO DATA FOUND
Contact Thermo Fisher Scientific

ABOUT Thermo Fisher Scientific


SECTOR: Patient Care

SUB SECTOR: Laboratory Equipment     

SPECIALITY: Laboratory Equipment

Neonatal sepsis is a leading cause of global mortality in children under five years old. According to the Global Sepsis Alliance, infections leading to sepsis are responsible for about one fifth of the world’s annual 2.7 million neonatal deaths, especially in South Asia and sub-Saharan Africa.

Prompt diagnosis and treatment of neonatal early onset sepsis is crucial to prevent severe morbidity and mortality. However, rapid and accurate diagnosis is often difficult in routine clinical practice because clinical manifestations of this condition can overlap with those of non-infectious conditions.

Here, the laboratory parameter B-R-A-H-M-S PCT can provide valuable information for the detection of neonatal sepsis from the first day of life.

A confident diagnosis

Procalcitonin (PCT) is the prohormone of the hormone calcitonin, and helps to differentiate bacterial from viral infections or other causes of systemic inflammation. Immediately after birth, newborns show a physiological elevation of PCT. Therefore, using PCT in neonates during their first 48-72 hours of life, age-specific PCT reference values apply: in healthy neonates, plasma PCT concentrations increase gradually after birth, reaching peak values at about 24 hours of age, and then decrease to normal values of less than 0.5_g/L by 48-72 hours of age.

The advantages of PCT-guided antibiotic therapy

Antibiotic treatment is started early in newborns who are at risk from infection in order to prevent a possible bacterial infection before it sets in. As a consequence, up to 7% of all newborn babies receive antibiotics within their first three days of life. However, a considerable number of these babies are exposed to antibiotics unnecessarily, as only 0.1% of them have such an infection.

Use of the B•R•A•H•M•S assay has been seen to lower treatment costs by 9%.

 

This overuse of powerful antibiotics can have a damaging effect on an infant’s developing immune system. Disruption of a baby’s microbiome has been linked to several chronic conditions, including allergies, obesity, diabetes and inflammatory bowel disease.

Recently, The Lancet published the results of a new multicenter, randomised controlled trial (NeoPInS) where 1,710 patients had been enrolled in 18 hospitals in the Netherlands, Switzerland, Canada and the Czech Republic in order to evaluate a B-R-A-H-M-S PCT-based clinical algorithm to guide antibiotic therapy decisions in term and near-term neonates with low likelihood of bacterial infection. The study demonstrated that PCT-guided decision-making was superior to the standard care approach, enabling a 15-19% reduction of antibiotic-therapy duration in these newborns.

It also suggests that higher adherence to the PCT algorithm could further increase this effect. As additional analysis revealed, the adherent group had a 25-hour shorter median duration compared with the non-adherent group, resulting in a 34% shorter AB duration compared with standard of care.

Thus, PCT can be an important tool, not only for the early detection of sepsis in neonates, but also to guide antibiotic treatment duration and reduce antibiotic exposure of neonates.

B-R-A-H-M-S PCT can provide valuable information for the detection of neonatal sepsis from the first day of life.


Thermo Fisher Scientific
168 Third Avenue Waltham, MA USA 02451
Waltham
Tel: 781-622-1000; 800-678-5599
02451
Massachusetts
United States of America
URL: www.thermofisher.com

Contact Thermo Fisher Scientific
Contact Thermo Fisher Scientific
Fast results for fast decisions

In the hospital environment, where making the correct decision quickly can have exponential benefits for clinical outcomes, speed and availability are of the essence. Thermo Fisher Scientific has therefore developed the first quantitative whole blood point-of-care procalcitonin test.

Download White Paper
PCT direct makes bedside diagnosis possible

In emergency departments, unforeseeable situations are routine. Ever-more rapid and reliable results are vital, and can have exponential benefits with regard to clinical outcomes and patient management. Thermo Fisher Scientific has developed the first quantitative whole-blood point-of-care procalcitonin (PCT) test to help medical staff to make informed decisions.

Download White Paper
Biomarkers guide safe antibiotic decisions

Overuse of antibiotics is a global problem, but the biomarker procalcitonin (PCT), such as the B·R·A·H·M·S PCT assay from Thermo Fisher Scientific, can help guide antibiotic stewardship and reduce resistance to the effects of these drugs. Basel University Hospital’s Dr Philipp Schuetz from the department of internal medicine discusses the importance of the biomarker.

Download White Paper
Improved antimicrobial susceptibility testing

Accurate antimicrobial susceptibility testing affects not only sepsis patients, but also those around them should the infection have a chance to spread. Professor Rafael Canton of the Ramón and Cajal University Hospital explains why the continuous development of testing products – such as those created by Thermo Fisher Scientific – is essential.

Download White Paper
Contact Thermo Fisher Scientific
Thermo Fisher Scientific Launches CE-IVD Marked Panel to Detect Most Common Gastrointestinal Bacteria

CARLSBAD, Calif.--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TaqPath Enteric Bacterial Select Panel, a CE-IVD marked panel designed to detect common gastrointestinal (GI) bacteria and help enable clinicians to identify the root cause of an infection and administer the most appropriate treatment to their patients more quickly. The panel was validated and registered under IVDD in May 2022.

Contact Thermo Fisher Scientific
Contact Thermo Fisher Scientific
Contact Thermo Fisher Scientific
Contact Thermo Fisher Scientific
Contact Thermo Fisher Scientific

Thermo Fisher Scientific - Procalcitonin for neonatal sepsis diagnosis and safe antibiotic guidance

Neonatal sepsis is a leading cause of global mortality in...